Buy 5-Amino-1MQ 50mg

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme expressed at high levels in white adipose tissue (WAT) and liver that catalyses the methylation of nicotinamide (a form of vitamin B3) using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). NNMT occupies a central position in cellular metabolic regulation because it simultaneously consumes two critical metabolic intermediates: nicotinamide—a precursor to NAD+—and SAM—the universal methyl donor for epigenetic and biochemical methylation reactions. NNMT is significantly overexpressed in obese versus lean adipose tissue, creating a state of relative NAD+ precursor depletion and methyl-group insufficiency in adipocytes that promotes fat accumulation and suppresses energy expenditure. By inhibiting NNMT, 5-Amino-1MQ produces two simultaneous metabolic consequences. First, it elevates intracellular nicotinamide concentrations and redirects nicotinamide flux toward NAD+ synthesis via the salvage pathway (nicotinamide phosphoribosyltransferase/NAMPT → nicotinamide mononucleotide/NMN → NAD+ via NMNAT). Elevated NAD+ is the essential cofactor for sirtuin deacylases (SIRT1–SIRT3) and poly(ADP-ribose) polymerases (PARPs), enzymes that regulate mitochondrial biogenesis, fatty acid oxidation, and glucose metabolism. SIRT1 activation by elevated NAD+ deacetylates and activates PGC-1alpha—the master regulator of mitochondrial biogenesis—and deacetylates PPAR-alpha, enhancing its transcriptional activation of fatty acid oxidation genes. The net result in adipocytes is a shift toward oxidative rather than lipogenic metabolism. Second, NNMT inhibition preserves SAM availability, maintaining the cellular methyl donor pool. SAM-dependent methylation reactions are critical for epigenetic gene regulation: SAM is the substrate for DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs), including the H3K4 methyltransferase complex that activates gene expression at metabolic loci. In adipocytes, reduced SAM depletion by NNMT inhibition restores methylation capacity at the promoters of thermogenic and oxidative metabolism genes—including UCP1 (uncoupling protein 1 in brown and beige adipocytes) and PGC-1alpha—that are epigenetically silenced in obese WAT. This epigenetic re-activation of thermogenic capacity represents a mechanism fundamentally different from any GLP-1-class or GH-fragment peptide: 5-Amino-1MQ does not suppress appetite or stimulate lipolysis directly; instead, it rewires adipocyte gene expression to favour energy expenditure over storage. The anti-adipogenic effect of NNMT inhibition is perhaps the most distinctive mechanistic feature. In preadipocyte differentiation models, 5-Amino-1MQ treatment suppresses the expression of key pro-adipogenic transcription factors—PPAR-gamma, C/EBP-alpha, C/EBP-beta, and adiponectin—during the differentiation cascade, substantially reducing the conversion of preadipocytes into mature lipid-storing adipocytes. This upstream block on adipocyte expansion means that 5-Amino-1MQ addresses not only existing adipose tissue (via metabolic reprogramming toward oxidation) but also the recruitment of new adipocytes that would otherwise expand fat depots. The combination of NAD+ restoration, SIRT1/PGC-1alpha pathway activation, epigenetic thermogenesis gene reactivation, and preadipocyte differentiation suppression creates a uniquely comprehensive anti-obesity mechanism that operates entirely independently of appetite regulation.

The 50 mg vial of 5-Amino-1MQ provides a practical quantity for research protocols investigating NNMT inhibition as a standalone metabolic intervention or as a complement to peptide-based fat-loss protocols. Unlike GLP-1 receptor agonists—which require weekly subcutaneous injection—5-Amino-1MQ is a small molecule that can be administered orally or via injection, offering more flexible protocol design. Typical research doses used in preclinical models scale to human equivalents in the range of 50–200 mg per day; the 50 mg vial provides sufficient material for several weeks of research at these dose levels, enabling proper characterisation of metabolic responses before committing to larger quantities. The most scientifically interesting protocol application for 5-Amino-1MQ in 2025–2026 is as a complement to GLP-1-class agents. The mechanistic rationale is compelling: GLP-1R agonism reduces caloric intake and mobilises adipose stores by creating a caloric deficit, while NNMT inhibition simultaneously reprograms adipose tissue metabolism to favour oxidation over re-esterification and suppresses new adipocyte recruitment. These mechanisms address entirely different aspects of adipose biology—intake restriction versus metabolic reprogramming—and there is no theoretical mechanism for interference between them. Preclinical combination studies are underway in multiple research laboratories, though published human combination data are not yet available as of early 2026. From a quality standpoint, 5-Amino-1MQ's relatively simple small-molecule structure (molecular weight approximately 174 Da) means that HPLC purity verification is straightforward and highly reliable. Purity above 99% is achievable and should be the standard when evaluating supplier quality. Nuclear magnetic resonance (NMR) spectroscopy provides definitive structural confirmation and is the gold-standard identity test for small molecules. Researchers should request both HPLC purity data and NMR spectra when sourcing 5-Amino-1MQ, and should store the compound at room temperature in a desiccated, light-protected container to prevent oxidative degradation of the quinolinium ring system.

5-Amino-1MQ occupies a mechanistically unique space in the fat-loss compound landscape. All GLP-1-class agents—semaglutide, tirzepatide, retatrutide—and amylin-class agents like cagrilintide, and GH-fragment agents like AOD9604, operate through receptor-mediated signalling: they bind a receptor, activate a second-messenger cascade, and produce acute cellular responses. 5-Amino-1MQ operates fundamentally differently: by inhibiting NNMT, it modifies the substrate availability for NAD+ biosynthesis and epigenetic methylation reactions, producing durable changes in adipocyte gene expression programs that persist beyond the period of active compound administration. This persistence of effect—dependent on the time required for epigenetic marks to be re-established or reversed—is both the most interesting and the most scientifically uncertain aspect of the compound. Against the GLP-1 class, 5-Amino-1MQ is not a competitive alternative—it does not produce the 15–25% weight loss observed with semaglutide, tirzepatide, or retatrutide in clinical trials. Its value proposition is different: it targets adipose tissue biology directly, at the level of differentiation and metabolic programming, rather than through appetite suppression. In this respect, it is more analogous to lifestyle interventions that improve metabolic health through tissue-level adaptations than to receptor-based pharmacological interventions that produce immediate appetite and energy intake changes. For researchers interested in the intersection of NAD+ metabolism, epigenetics, and adipose tissue function, 5-Amino-1MQ represents the most pharmacologically specific available tool for interrogating the NNMT pathway in vivo.